Pharmesis International (SGX:BFK) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
31 GF Score
Price S$0.11
GF Value S$0.09
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pharmesis International Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Pharmesis International's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

SGX:BFK vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmesis International Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Pharmesis International's Margin of Safety % (DCF Dividends Based) falls into.


SGX:BFK
31GF Score
Pharmesis International Ltd SGX:BFK
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued. The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09. GuruFocus considers Pharmesis International to be Modestly Overvalued.

Key valuation signals for SGX:BFK:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score

Get the complete analysis for SGX:BFK

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.11
Price
S$0.09
GF Value